Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+NSCLC Patients

被引：78
|
作者：
Kowanetz, Marcin [1 ]
Zou, Wei [1 ]
Shames, David [1 ]
Cummings, Craig [1 ]
Rizvi, Naiyer [2 ]
Spira, Alexander [3 ,4 ]
Frampton, Garrett [5 ]
Leveque, Vincent [1 ]
Flynn, Susan [1 ]
Mocci, Simonetta [1 ]
Shankar, Geetha [1 ]
Funke, Roel [1 ]
Ballinger, Marcus [1 ]
Waterkamp, Daniel [1 ]
Chen, Daniel [1 ]
Sandler, Alan [1 ]
Hampton, Garret [1 ]
Amler, Lukas [1 ]
Hegde, Priti [1 ]
Hellmann, Matthew [6 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Columbia Univ, New York, NY USA
[3] US Oncol Res, The Woodlands, TX USA
[4] Virginia Canc Specialists Res Inst, Fairfax, VA USA
[5] Fdn Med, Cambridge, MA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
Immunotherapy; mutational load; NSCLC; Biomarkers;
D O I：
10.1016/j.jtho.2016.11.343
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA20.01
引用
收藏
页码：S321 / S322
页数：2
相关论文
共 50 条
  • [21] Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1-selected patients: Efficacy data from the BIRCH trial
    Peters, S.
    Carcereny Costa, E.
    Garassino, M. C.
    Christoph, D.
    Kurata, T.
    Chaft, J.
    Johnson, M. L.
    Mocci, S.
    Gettinger, S. N.
    Felip, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+NSCLC: Results from the randomized OAK study
    Gadgeel, S.
    Kowanetz, M.
    Zou, W.
    Hirsch, F. R.
    Kerr, K. M.
    Gandara, D. R.
    Barlesi, F.
    Park, K.
    McCleland, M.
    Koeppen, H.
    Ballinger, M.
    Sandler, A.
    Hegde, P. S.
    Rittmeyer, A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] CheckMate 227: Nivolumab plus Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden
    Mathias, C.
    Reck, M.
    Hellmann, M.
    Ramalingam, S.
    Brahmer, J.
    O'Byrne, K.
    Bhagavatheeswaran, P.
    Nathan, F.
    Borghaei, H.
    Paz-Ares, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S152 - S153
  • [24] Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS
    Lee, S. M.
    Han, B.
    Peters, S.
    Le, A. T.
    Huang, D.
    Wu, G.
    Cao, L.
    Pham, C. P.
    Zhao, J.
    Wang, K.
    Yang, N.
    Zhong, H.
    Hu, Y.
    Morris, S.
    Lam, V.
    Graupner, V.
    Gitlitz, B.
    Hoglander, E.
    Schulz, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S616 - S617
  • [25] Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma.
    Gibney, Geoffrey Thomas
    Tang, Shaojun
    Poorman, Kelsey
    Olszanski, Anthony J.
    Eisenberg, Burton Larry
    Mehmi, Inderjit
    Farma, Jeffrey M.
    In, Gino Kim
    Amin, Asim
    Rapisuwon, Suthee
    Vanderwalde, Ari M.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab
    Nie, Wei
    Qian, Jie
    Xu, Mi-Die
    Gu, Kai
    Qian, Fang-Fei
    Hu, Min-Juan
    Lu, Jun
    Gan, Lu
    Zhang, Xue-Yan
    Cao, Shu-Hui
    Li, Jing-Wen
    Wang, Yue
    Zhang, Bo
    Wang, Shu-Yuan
    Hu, Fang
    Li, Chang-Hui
    Zhong, Hua
    Han, Bao-Hui
    ONCOIMMUNOLOGY, 2020, 9 (01):
  • [27] Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
    Zhu, Jiaxin
    Zhang, Tiantian
    Li, Jiahao
    Lin, Junming
    Liang, Wenhua
    Huang, Wenjie
    Wan, Ning
    Jiang, Jie
    FRONTIERS IN PHARMACOLOGY, 2019, 10
  • [28] Efficacy of first-line (1L) nivolumab (N) plus ipilimumab (I) by tumor histologic subtype in patients ( pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
    Borghaei, H.
    Balli, D.
    Paz-Ares, L.
    Reck, M.
    Ramalingam, S. S.
    Brahmer, J. R.
    Ciuleanu, T-E.
    Pluzanski, A.
    Lee, J-S.
    Gainor, J.
    Schenker, M.
    Schoenfeld, A.
    Caro, R. Bernabe
    Ready, N.
    Lee, K. H.
    Zurawski, B.
    Audigier-Valette, C.
    Baxi, V.
    Geese, W.
    O'Byrne, K. J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S64 - S65
  • [29] Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+NSCLC
    Gandara, D. R.
    Reck, M.
    Morris, S.
    Cardona, A.
    Mendus, D.
    Ballinger, M.
    Rittmeyer, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 39 - 39
  • [30] Correlation of NFE2L2 mutation with higher tumor mutation burden (TMB), microsatellite instability (MSI) and PD-L1 expression in 3,716 cases of Chinese pan-cancer.
    Wu, Bin
    Li, Aijun
    Chen, Keji
    Chen, Lin
    Zhang, Qin
    Duan, Qianqian
    Xiao, Mingzhe
    Li, Mengmeng
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345